The Next Frontier in Management of Atopic Dermatitis: Therapies for Today and Tomorrow

Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

James Del Rosso, DO

Faculty

Adjunct Clinical Professor (Dermatology)
Touro University College of Osteopathic Medicine
Henderson, NV

Upon completion of this activity, the participant should be better able to:

Gain a deeper understanding of the current limitations and appropriate uses of AD therapies
Recognize the potential benefits of JAK-inhibitor therapy for their patients with atopic dermatitis
Evaluate the safety and efficacy of new emerging JAK inhibitors for atopic dermatitis
Apply clinically relevant monitoring options for the different JAK inhibitors
Educate patients and caregivers to improve outcomes of patients with AD through shared-decision making

This activity is designed for dermatologists and related healthcare providers who manage patients with Atopic Dermatitis.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Jointly provided by the Foundation for Research and Education in Dermatology and the University of Nevada, Reno School of Medicine.

The University of Nevada Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

This CME activity is supported by an educational grant from Pfizer.

Faculty Disclosures

James Del Rosso, DO

Consultant: Aclaris, Almirall, BioPharmX, Cassiopea, Celgene, Cutanea, Dermira, Encore, EPI Health, Ferndale, Foamix, Galderma, LEO LaRoche-Posay, Menlo Therapeutics, Novan, Ortho Dermatologics, Pfizer, Promius, Sanofi/Genzyme, Sonoma (Intraderm), Sol Gel, Sun Pharma, Verrica

Grant/Research Support: Abbvie, Aclaris, Almirall. Athenex, BioPharmX, Botanix, Celgene, Dermira, Foamix, Galderma, Genentech, LEO, Menlo Therapeutics, Novan, Ortho Dermatologics, Promius, Regeneron, Sanofi/Genzyme Sol Gel, Sun Pharma

Speakers’ Bureau or Honoraria: Aclaris, Almirall, Celgene, Cutane, Dermira, Encore, EPI Health, Galderma, Genetech, LEO, Ortho Dermatologics, Pfizer, Promius, Regeneron, Sanofi/Genzyme, Sol Gel, Sun Pharma, Verrica

[fc+228]